SKP2 and neoplasm: Reduction in SKP2:FOXA1 indicates that pharmaceutical inhibition of SKP2 is sufficient to target the SKP2–FOXA1 interplay and subsequently increase FOXA1 protein levels, while simultaneously suppressing tumor proliferation (Fig. S12a–c).